Srivastava A
Department of Medicine, Indiana University of School of Medicine, Indianapolis 46202-5120, USA.
Blood Cells. 1994;20(2-3):531-6; discussion 536-8.
It is becoming increasingly clear that the parvovirus-based vectors may prove to be a useful alternative to the more commonly used retroviral vectors in human gene therapy. Specifically, the adeno-associated virus 2 (AAV), a human parvovirus, has gained particular attention in view of its nonpathogenic nature as well as its remarkable site-specificity of integration into the human chromosome. Using the recombinant AAV vector system, it is feasible to obtain high-efficiency transduction of slow- or non-cycling primary hematopoietic stem and progenitor cells, without the need for prestimulation with cytokines, which could potentially lead to differentiation of these cells before transplantation.
越来越明显的是，在人类基因治疗中，基于细小病毒的载体可能被证明是比更常用的逆转录病毒载体更有用的替代品。具体而言，腺相关病毒2（AAV），一种人类细小病毒，鉴于其非致病性质以及其整合到人类染色体中的显著位点特异性而受到特别关注。使用重组AAV载体系统，可以高效转导缓慢或非循环的原代造血干细胞和祖细胞，而无需用细胞因子进行预刺激，因为细胞因子可能会在移植前导致这些细胞分化。
